We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COVID-19-associated mucormycosis—elucidating the etiology of this emerging entity.
- Authors
Sakthivel, P; Ish, P
- Abstract
COVID-19-associated mucormycosis - elucidating the etiology of this emerging entity 48/61 (78.7%) patients who had CAM received glucocorticoid treatment for COVID-19 management and had no other comorbidities indicating possible steroid association for CAM. With great interest, we read the article by Sarda I et al. i [1] and would like to congratulate the authors for discussing the emerging epidemic of COVID-19-associated Mucormycosis (CAM) and the risk factors including excessive use of steroids, hyperglycemia, home management and hyperferritinemia, prolonged face masks and industrial oxygen.
- Subjects
MUCORMYCOSIS; ETIOLOGY of diseases; COVID-19; SARS-CoV-2 Delta variant; MYCOSES; COVID-19 treatment
- Publication
QJM: An International Journal of Medicine, 2022, Vol 115, Issue 6, p421
- ISSN
1460-2725
- Publication type
Article
- DOI
10.1093/qjmed/hcab195